huCART19-IL18 in CD19+ Cancers

This is a Phase I study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of huCART19-IL18 cells in patients with CD19+ cancers. The study will take place in two parts: an initial Dose-Finding Phase and an Expansion Phase. In the dose-finding phase, the maximum tolerated dose will be determined using a Bayesian Optimal Interval (BOIN) design within each of the following disease-specific cohorts: * Cohort A: Non-Hodgkin Lymphoma (Active, Not Recruiting) * Cohort B: Chronic Lymphocytic Leukemia (Active, Not Recruiting) * Cohort C: Acute Lymphoblastic Leukemia (Active, Not Recruiting) * Cohort D (Expansion Phase): Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia (Active, Not Recruiting) will evaluate changes to cell activation method in the huCART19-IL18 manufacturing process using the recommended dose for expansion (RDE) arising out of the dose-finding phase.